Tag Archives: NSABP

Colon Cancer Prevention Trial Seeking New Patients

Can drugs used to help lower cholesterol also keep colon cancer from returning?  Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) are seeking patients for a one-year clinical trial to determine if cholesterol-lowering drugs (statins) might help prevent the growth of precancerous (adenomatous) polyps and/or recurrent colorectal cancer. The NSABP trial is sponsored by the National Cancer Institute and has recently expanded to include patients with stage 0, I, II or III colon cancer at diagnosis. Patients can enter the study up to one year after their initial diagnosis. In 2011, Fight Colorectal Cancer’s late Director of Research Communications Kate Murphy wrote about the trial and its efforts

C-08 Avastin Trial Didn't Meet Primary Goal

When Avastin® (bevacizumab) was added to standard chemotherapy after surgery, it didn’t reduce the risk that early stage colon cancer would return, according to a press release this morning from Genentech. NSABP C-08 randomly assigned patients with stage II or III colon cancer to FOLFOX chemotherapy with or without additional Avastin.  During the Phase III clinical trial, all patients received FOLFOX (oxaliplatin, leucovorin, and infused 5-FU) every two weeks for six months.  Half also got Avastin with each treatment plus an additional six months of Avastin only. The study’s primary objective was disease-free survival, defined as lack of recurrence, another new cancer, or death for any reason.  According to Genentech, adding Avastin to

Top